Tumor flare with T-cell-engaging bispecific antibodies

This publication has 10 references indexed in Scilit:

• Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
  Journal of Clinical Oncology, 2021
• Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
  The Lancet, 2020
• The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
  Signal Transduction and Targeted Therapy, 2020
• KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
  New England Journal of Medicine, 2020
• Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  New England Journal of Medicine, 2019
• Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
  The Lancet Oncology, 2019
• Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy
  Bone Marrow Transplantation, 2018
• Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
  New England Journal of Medicine, 2018
• Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
  New England Journal of Medicine, 2017
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
  The Lancet, 2015